Alnylam Pharmaceuticals
ALNY
#662
Rank
S$40.20 B
Marketcap
$310.53
Share price
-4.68%
Change (1 day)
56.44%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Operating Margin for Alnylam Pharmaceuticals (ALNY)

Operating Margin as of March 2025 (TTM): -16.78%

According to Alnylam Pharmaceuticals 's latest financial reports and stock price the company's current Operating Margin is -16.78%. At the end of 2024 the company had an Operating Margin of -16.79%.

Operating Margin history for Alnylam Pharmaceuticals from 2003 to 2024

Operating Margin at the end of each year

Year Operating Margin Change
2024-16.79%-29.21%
2023-23.71%-78.17%
2022-108.63%7.63%
2021-100.93%-41.86%
2020-173.60%-56.91%
2019-402.85%-60.33%
2018-1,015.48%86%
2017-545.95%-37.22%
2016-869.63%23.21%
2015-705.83%-10.92%
2014-792.32%306.56%
2013-194.88%11.54%
2012-174.73%150.82%
2011-69.66%62.06%
2010-42.98%-8.07%
2009-46.76%76.12%
2008-26.55%-83.16%
2007-157.61%7.45%
2006-146.68%-80.71%
2005-760.53%0.84%
2004-754.18%-93.51%
2003-11,618.18%

Operating Margin for similar companies or competitors

Company Operating Margin Operating Margin differencediff. Country
-17,247.50% 102,686.05%๐Ÿ‡บ๐Ÿ‡ธ USA
33.65%-300.54%๐Ÿ‡บ๐Ÿ‡ธ USA
14.67%-187.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-1.45%-91.36%๐Ÿ‡บ๐Ÿ‡ธ USA
-118.00% 603.22%๐Ÿ‡บ๐Ÿ‡ธ USA
26.37%-257.15%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
15.12%-190.11%๐Ÿ‡ซ๐Ÿ‡ท France
-7.76%-53.75%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

What is a company's Operating Margin?

The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.